Table 4.

Multivariate Analysis of Prognostic Factors for PFS and OS

Variable	OS				PFS
	Mean	SD	95% CI	Pr (Beneficial Effect)	Mean	SD	95% CI	Pr (Beneficial Effect)
Intercept	1.02	0.34	0.38, 1.68	--	0.89	0.33	0.25, 1.55	--
Age	−0.008	0.02	−0.06, 0.04	0.381	−0.02	0.02	−0.07, 0.03	0.215
Race=Non-white	0.11	0.33	−0.52, 0.76	0.627	0.19	0.35	−0.48, 0.88	0.701
Bortezomib (1mg) vs. No Botezomib.	0.14	0.36	−0.57, 0.82	0.653	0.05	0.35	−0.64, 0.72	0.56
Bortezomib (1.5mg) vs. No Botezomib	0.21	0.38	−0.53, 0.95	0.716	0.1	0.38	−0.64, 0.84	0.602
Gender=Male	−0.05	0.32	−0.68, 0.57	0.439	−0.1	0.31	−0.72, 0.51	0.378
Stage II vs. I	0.01	0.41	−0.79, 0.82	0.514	0.17	0.42	−0.64, 0.97	0.651
Stage III vs. I	−0.15	0.43	−1.01, 0.68	0.366	−0.28	0.44	−1.16, 0.58	0.266
Stage Unknown vs. I	−0.25	0.41	−1.02, 0.55	0.267	−0.5	0.41	−1.29, 0.30	0.11
HR Cytogenetics	−0.71	0.44	−1.54, 0.18	0.058	−0.98	0.43	−1.79, −0.10	0.016
Maintenance Therapy Before Transplant	0.07	0.42	−0.71, 0.94	0.555	0.14	0.43	−0.66, 1.02	0.618
Chemo-Mobilization Before Transplant	0.08	0.38	−0.64, 0.85	0.571	−0.14	0.38	−0.84, 0.63	0.351

HR: high-risk